APLS
Price
$24.96
Change
+$0.29 (+1.18%)
Updated
Dec 11 closing price
Capitalization
3.16B
82 days until earnings call
Intraday BUY SELL Signals
CRSP
Price
$56.67
Change
-$1.42 (-2.44%)
Updated
Dec 12, 04:59 PM (EDT)
Capitalization
5.54B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

APLS vs CRSP

Header iconAPLS vs CRSP Comparison
Open Charts APLS vs CRSPBanner chart's image
Apellis Pharmaceuticals
Price$24.96
Change+$0.29 (+1.18%)
Volume$1.81M
Capitalization3.16B
CRISPR Therapeutics AG
Price$56.67
Change-$1.42 (-2.44%)
Volume$40.84K
Capitalization5.54B
APLS vs CRSP Comparison Chart in %
View a ticker or compare two or three
VS
APLS vs. CRSP commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Buy and CRSP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (APLS: $24.97 vs. CRSP: $58.09)
Brand notoriety: APLS and CRSP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 67% vs. CRSP: 55%
Market capitalization -- APLS: $3.16B vs. CRSP: $5.54B
APLS [@Biotechnology] is valued at $3.16B. CRSP’s [@Biotechnology] market capitalization is $5.54B. The market cap for tickers in the [@Biotechnology] industry ranges from $113.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 1 FA rating(s) are green whileCRSP’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 1 green, 4 red.
  • CRSP’s FA Score: 0 green, 5 red.
According to our system of comparison, APLS is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 5 TA indicator(s) are bullish while CRSP’s TA Score has 4 bullish TA indicator(s).

  • APLS’s TA Score: 5 bullish, 5 bearish.
  • CRSP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, APLS is a better buy in the short-term than CRSP.

Price Growth

APLS (@Biotechnology) experienced а +12.51% price change this week, while CRSP (@Biotechnology) price change was -0.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was +4.75%, and the average quarterly price growth was +65.86%.

Reported Earning Dates

APLS is expected to report earnings on Mar 04, 2026.

CRSP is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Biotechnology (+1.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($5.54B) has a higher market cap than APLS($3.16B). CRSP YTD gains are higher at: 47.586 vs. APLS (-21.764). APLS has higher annual earnings (EBITDA): -178.43M vs. CRSP (-533.5M). CRSP has more cash in the bank: 1.72B vs. APLS (370M). CRSP has less debt than APLS: CRSP (215M) vs APLS (470M). APLS has higher revenues than CRSP: APLS (755M) vs CRSP (35M).
APLSCRSPAPLS / CRSP
Capitalization3.16B5.54B57%
EBITDA-178.43M-533.5M33%
Gain YTD-21.76447.586-46%
P/E Ratio69.35N/A-
Revenue755M35M2,157%
Total Cash370M1.72B21%
Total Debt470M215M219%
FUNDAMENTALS RATINGS
APLS vs CRSP: Fundamental Ratings
APLS
CRSP
OUTLOOK RATING
1..100
2517
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
4845
P/E GROWTH RATING
1..100
2975
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (72) in the Biotechnology industry is in the same range as APLS (86) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

CRSP's SMR Rating (95) in the Biotechnology industry is in the same range as APLS (98) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

CRSP's Price Growth Rating (45) in the Biotechnology industry is in the same range as APLS (48) in the Medical Distributors industry. This means that CRSP’s stock grew similarly to APLS’s over the last 12 months.

APLS's P/E Growth Rating (29) in the Medical Distributors industry is somewhat better than the same rating for CRSP (75) in the Biotechnology industry. This means that APLS’s stock grew somewhat faster than CRSP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSCRSP
RSI
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 24 days ago
80%
Bearish Trend 23 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signal:
Gain/Loss:
CRSP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HBGHX15.370.10
+0.65%
Hartford Healthcare HLS IB
PIIJX16.860.05
+0.30%
Principal Diversified Intl J
FMACX49.300.11
+0.22%
American Funds AMCAP F3
MLPRX4.68N/A
N/A
Invesco SteelPath MLP Income C
NUEIX24.31N/A
N/A
Northern US Quality ESG I

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with IMVT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
+1.15%
IMVT - APLS
39%
Loosely correlated
+5.31%
VNDA - APLS
39%
Loosely correlated
-2.22%
MRSN - APLS
38%
Loosely correlated
+0.43%
NUVL - APLS
37%
Loosely correlated
+0.16%
DNLI - APLS
37%
Loosely correlated
-1.14%
More